Pharmacology of 5-HT2 Modulation of Amygdala & Hypothalamus in Anxiety Disorders by Jiang, Xiaolong et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Pharmacology of 5-HT2 Modulation  
of Amygdala & Hypothalamus  
in Anxiety Disorders 
Xiaolong Jiang1, Aiqin Chen2, Stanley Smerin3, Lei Zhang3 and He Li3  
1Department of Pharmacology University of Virginia 
2Fujian Medical University, 
Department of Psychiatry and Centre for the Study of Traumatic Stress 
3Uniformed Services University of the Health Sciences 
1,3USA 
2PRC  
1. Introduction 
“Anxiety disorders” is a blanket term covering several different forms of abnormal and 
pathological fear and anxiety, and is often comorbid with other mental disorders, 
particularly clinical depression. These conditions are often related to stressful life 
experiences, especially when chronic and traumatic. Stress appears to act as a predisposing 
and precipitating factor in these psychiatric conditions (Strohle and Holsboer, 2003). One 
particular, extreme case is post traumatic stress disorder (PTSD), a chronic anxiety disorder 
developed in the aftermath of traumatic stress exposure and persisting long after the 
removal of the participating stressors.  
Advances in cellular and molecular biology and imaging technology have opened several 
lines of inquiry into the pathogenesis and pharmacotherapy of the anxiety disorders. 
Dysregulation of neurotransmitter systems, alteration of signal transduction pathways, and 
reshaping of brain circuitry are all being explored. The availability of animal models of 
anxiety disorders developed from the “learned helplessness” stress paradigm, in particular, 
has been a great aid in elucidation of disease etiology and pathophysiology, as well as in the  
development of more efficacious pharmacological interventions (Drevets, 2003;Maier and 
Watkins, 2005;Minor and Hunter, 2002). Among several hypotheses for the pathogenesis of 
anxiety disorders, dysregulation of the serotonergic system has received particular attention 
in the field since the evidence from both preclinical and animal model studies is substantial 
and often complementary. In this chapter, we focus on a subset of the serotonergic system, 
the 5-HT2 receptor system, and review both clinical and preclinical evidence regarding the 
involvement of this receptor in the pathophysiology of anxiety disorders. 
2. Neuronal circuitry associated with anxiety disorders 
The phenotypic complexity of anxiety disorders indicates that multiple neurotransmitter 
systems and brain structures are involved in the pathogenesis of such disorders. The 
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neuronal circuits associated with anxiety disorders appear to involve distributed and 
interconnected brain structures, including the amygdala, frontal cortex, and amygdala. These 
structures are also principal recipient regions of the ascending serotonergic pathway 
originating in the dorsal raphé nucleus (DRN), and with this innervation, form the important 
DRN-corticolimbic pathway in the brain, a critical component of the neuronal network 
associated with regulation of stress/emotional response (Graeff et al., 1993;Spannuth et al., 
2011;Hale et al., 2010;Kawano et al., 1992). Dysregulation of this pathway has long been 
recognized in the occurrence of stress-related psychiatric syndromes, including depressive 
disorders and anxiety disorders (Southwick et al., 1999;van Praag, 2004a). Among various 
serotonin (5-hydroxytryptamine 5-HT) receptor systems, alterations of the postsynaptic 5-HT2 
receptor system in the forebrain may be particularly relevant to the pathophysiology of stress-
related psychiatric conditions. There is a general consensus among many PET scan studies that 
there is decreased forebrain 5-HT2A receptor density in drug-naïve depressed patients (Akin et 
al., 2004;Malone et al., 2006;Messa et al., 2003;Mintun et al., 2004;Sheline et al., 2004). Several 
studies also showed that the therapeutic action of antidepressants is associated with an 
increase and/or normalization in brain 5-HT2A receptor density (Massou et al., 1997;Messa et 
al., 2003;Sheline et al., 2004;Zanardi et al., 2001). Thus, it is hypothesized that diminished 5-
HT2A receptor signaling in the forebrain is associated with the cognitive syndrome observed in 
PTSD and certain subgroups of depressive illnesses (van Praag, 2004a;van Praag, 2004b).  
Animal studies also suggest the involvement of forebrain 5-HT2 receptor signaling in 
stress-related psychiatric conditions. For example, activation of 5-HT2C receptors in the 
amygdala during traumatic stress is necessary for the expression of anxiety-like behaviors 
after traumatic stress exposure (Christianson et al., 2010). Inescapable stress induces a 
decrease in 5-HT2A receptor expression in the amygdala, and hippocampus (Dwivedi et 
al., 2005), and hypothalamus (Dwivedi et al., 2005;Petty et al., 1997;Wu et al., 1999), and 
the decrease in the number of 5-HT2A receptors in the hypothalamus and hippocampus 
appears to be specifically associated with behavioral depression after exposure to stress 
(Dwivedi et al., 2005). In addition, alterations of 5-HT2A receptor signaling in the 
amygdala have been specifically implicated in the initiation of lasting changes in anxiety-
like behavior following predator stress and traumatic stress (Adamec et al., 2004;Jiang et 
al., 2009). Thus stress-related psychiatric syndromes, including various anxiety disorders, 
may evolve from altered 5-HT2 receptor signaling in the forebrain (Graeff et al., 
1996;Menard and Treit, 1999).  
3. 5-HT2 receptor expression and its neuronal function in the amygdala  
The region of the forebrain involved in anxiety disorders that will be focused on herein is 
the amygdala, a brain region located deep in the anterior temporal lobe. It is believed that 
abnormal neural excitability and plasticity in the amygdala is an essential feature of 
multiple types of anxiety disorders and may be directly linked with the expression of the 
symptoms associated with stress-related psychiatric conditions. 5-HT2 receptors appear to be 
highly expressed in the amygdala (Morilak et al., 1994;Pompeiano et al., 1994;Wright et al., 
1995) and thus may serve an important modulatory role in fear and anxiety response. The 5-
HT2 receptor has three subfamilies, including 5-HT2A, 5HT2B and 5-HT2C. Both 5-HT2A and 5-
HT2C receptors have been shown to be highly expressed in the amygdala(Xu and Pandey, 
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2000;Pompeiano et al., 1994;Jiang et al., 2009). The immunofluorescence data from several 
laboratories show that the 5-HT2A receptor labeling is primarily localized to the soma and 
dendrites of interneuron-like cells in the basolateral amydala (BLA), and that the majority of 
the 5-HT2A signal overlapped with the labeling for the interneuron marker parvalbumin, 
indicating the 5-HT2A receptor is localized to the interneuron. Interestingly, 5-HT2A receptor 
immunofluorescence was found to be rarely observed in the pyramidal cells of the BLA, 
indicating that 5-HT2A receptor expression is restricted to interneurons in the BLA, while the 5-
HT2C receptor may be primarily expressed on the pyramidal cells. In addition, the receptors 
density of various subtypes of 5-HT2 receptor is dynamically regulated by age, gender, 
hormones and various experimental conditions associated with anxiety (Chen et al., 
1995a;Chen et al., 1995b;Jiang et al., 2009). 
The specific expression of 5-HT2A and 5-HT2C receptors in different neuronal components of  
the amygdala may be related to their specific modulation of neuronal functions in the 
amygdala and of behavioral responses. Indeed, the observations from several laboratories, 
particularly our own, support this contention, and activation of 5-HT2A and 5-HT2C 
receptors induce different neuromodulation in the amygdala and different behavioral 
responses. Restriction of 5-HT2A receptors to interneurons in the amygdala suggests that 5-
HT2A receptors participate in inhibitory modulation of the amygdala circuitry. Indeed, a 
recent publication has shown that the 5-HT2A receptor is the primary receptor responsible 
for the serotonerigc facilitation of GABA release in the amygdala (Jiang et al., 2009). 
Activation of this receptor on amygdala interneurons appears to induce the depolarization 
of the interneurons and facilitate the GABA release from these neurons (Jiang et al., 2009). 
Since any mediator facilitating GABAergic synaptic transmission in the BLA should induce 
an anxiolytic effect, it would be expected that the 5-HT2A receptor is anxiolytic. Activation of 
this receptor has been observed to induce an anxiolytic effect, although that this action is 
mediated by the amygdala has not been confirmed (Ripoll et al., 2006;Bourin et al., 2005;Nic 
Dhonnchadha et al., 2003). 
Activation of 5-HT2C receptors in the BLA, in contrast, induce anxiety-like effects in animals 
(Hackler et al., 2006;Campbell and Merchant, 2003;Antonio Pedro de Mello Cruz et al., 
2005,Christianson et al., 2010), suggesting that 5-HT2C receptor activation enhances neuronal 
excitability in the amygdala. The data from our laboratory suggest that the 5-HT2C receptors 
may play a modulatory role by promoting NMDA function on pyramidal cells in the 
amygdala. For example, application of the 5HT2 receptor agonist 1-(2,5)-dimethoxy-4-
iodophen-2-aminopropane (DOI) enhances NMDA receptor-mediated excitatory 
postsynaptic potentials and calcium influx, and as a consequence, transforms theta-burst 
stimulated synaptic plasticity from short-term potentiation (STP) to long-term potentiation 
(LTP) in the BLA (Chen et al., 2003). The facilitating effects of DOI were blocked by the 5-
HT2 receptor antagonist, ketanserin, and by the 5-HT2C-receptor selective antagonist, 
RS102221 (Chen et al., 2003). Therefore, activation of the 5HT2C receptor may induce anxiety-
like effects in animals primarily by enhancing NMDA receptor function in the BLA. 
In conclusion, 5-HT2A and 5-HT2C receptors appear to be expressed in the different 
components of the amygdala neuronal circuitry and have opposite functional roles in 
modulating the amygdala circuitry and the behavioral  responses associated with this 
circuitry. Pharmacotherapy tailored to modulating the effect of 5-HT2A and 5-HT2C receptors 
in the BLA may have therapeutic implications in anxiety disorders.  
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4. Anxiety disorders and dysregulation of 5-HT2 modulated signaling 
pathways in the amygdala 
Since 5-HT2 receptors in the amygdala play important neuromodulatory roles in fear and 
stress responses, dysregulation of 5-HT2 receptor signaling in the amygdala may result in 
the abnormal and pathological fear and stress responses manifested in different forms of 
anxiety disorders. Specifically, any condition promoting 5-HT2C receptor signaling or 
decreasing 5-HT2A receptor signaling would predispose the amygdala to over-respond to 
any sensory input, and anxiety status may ensue. Indeed, overexpression of 5-HT2C 
receptors in forebrain, particularly in the amygdala, has been observed to lead to elevated 
anxiety in animals (Kimura et al., 2009). Clinical data and preclinical data also suggest that 
diminished 5-HT2A receptor signaling in the forebrain, including the amygdala, may 
contribute to pathogenesis of the cognitive syndrome observed in PTSD and certain 
subgroups of depressive illnesses (van Praag, 2004a;van Praag, 2004b). 
 
 
Fig. 1. 5-HT2 receptors in the BLA and in the paraventricular nucleus (PVN) of the 
hypothalamus:  Immunohistochemistry  with specific anti-5HT2 receptor antibodies reveals 
5HT2 receptors on somata in both the BLA and PVN.  In the BLA, 5HT2 receptors appear on 
dendrites and axons as well (see text for details.) 
More convincing data come from animal studies. Chronic or traumatic stress, a primary 
etiologic factor for anxiety disorder, particularly PTSD, appears to readily impair central 5-
HT2A receptor signaling, including in the amygdala (Abi-Saab et al., 1999;Dwivedi et al., 
2005;Jiang et al., 2009;Wu et al., 1999), suggesting that stress induces anxiety in animals by 
impairing 5-HT2A signaling in the forebrain, particularly in the amygdala. If this is true, then it 
would be expected that 5-HT2A receptor antagonists, administered during stress, would 
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prevent the subsequent occurrence of abnormalities remisicent of anxiety disorders in animals 
since the antagonists would prevent the receptors being downregulated and impaired. 
Indeed, several laboratories have observed that adminstration of 5-HT2A receptor from 
antagonists during stress averts several behavorial manisfestations of anxiety status in 
animals, including exaggerated  acoustic startle response and open arm avoidance in the plus 
maze (Adamec et al., 2004;Jiang et al., 2009). In conclusion, alterations of 5-HT2 receptor 
signaling, particularly 5-HT2A receptor signaling in the amygdala, may be a significant 
contributor in the pathogenesis of anxiety disorders.  
Alterations of 5-HT2 receptor signaling could result from receptor downregulation and  
degradation, or the disturbance of downstream signal pathways. The 5-HT2 receptor is a G 
protein-coupled receptor and activation of the receptor leads to activation of 
phosphoinositide phospholipase C (PLC) and accumulation of D-myo-inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG), each of which then leads to its own signaling 
cascade, mediating a diverse array of physiological responses (Hall et al., 1999;Schmid and 
Bohn, 2009). Several studies suggest that distubance of downstream signal pathways of 5-
HT2 receptor ,including abnormal PLC and 
PKC activity, may also be involved in the pathophysiology of stress-related psychiatric 
conditions (Akin et al., 2004). Other potential candidates involved in stress-related 
psychiatric syndromes are those molecules associated with receptor desensitization and 
internalization. Like other similar receptors, 5-HT2 receptors, require the participation of G 
protein–coupled receptor kinases (GRKs) and β-arrestin in their desensitization and 
internalization (Schmid et al., 2008;Whalen et al., 2011;Lefkowitz, 1998;Gray et al., 2003; 
Gray et al., 2001;Bohn and Schmid, 2010), so these molecules could be novel potentially 
therapeutic targets for anxiety disorders. The most recent finding indeed reveals that β-
arrestin-2 is highly expressed in the amygdala and participates in the acquisition and 
consolidation of fear memories. Manipulation of this molecular signaling pathway thus may 
be able to regulate the abnormal fear memory associated with certain anxiety disorders (Li 
et al., 2009). 
5. Hypothalamic 5-HT2 receptors, stress, and energy homeostasis 
Another forebrain region critically involved in the pathophysiology of stress-related 
psychiatric conditions is the hypothalamus. The hypothalamus is a center integrating 
neuronal and endocrine systems for autonomic functions, including those underlying 
feeding and behavioral arousal (Jo and Role, 2002a;Gerashchenko and Shiromani, 2004). 
Different neuronal phenotypes and neurotransmitter systems in the hypothalamus play 
dynamic roles in maintaining homeostasis and neuroendocrine circadian rhythm in the face 
of acute and chronic internal and external challenges (Harris et al., 2006a). In addition to 
multiple neuropeptides, monoamines, and cholinergic and purinergic systems, serotonin 
plays a critical role in the defensive response to stressful environmental stimuli and energy 
homeostasis (Jo and Role, 2002a;Jo and Role, 2002b;Pyner, 2009). 
The paraventricular nucleus (PVN) of the hypothalamus secretes corticotropin releasing 
factor (CRF), a key mediator in the stress response, and receives heavy innervation from the 
serotonergic projection. This nucleus expresses both 5-HT2A and 5-HT2C receptors (Kawano 
et al., 1992;Li et al., 2003) (Figure 1) and secretion of CRF appears to be regulated by both 5-
HT2A and 5-HT2C receptor ligands (Heller and Baraban, 1987;Heisler et al., 2007). These 
receptors in the PVN are also part of the mechanism mediating feeding and body weight 
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(Leibowitz et al., 1989;Tachibana et al., 2001). Dysregulation of 5-HT2 receptor systems in the 
PVN is thus implicated in anxiety disorders and several affective disorders associated with 
loss of energy homeostasis. 
Indeed, chronic or traumatic stress, a primary etiologic factor for anxiety disorders, readily 
decreases central 5-HT2A receptor signaling in the hypothalamus, in addition to other 
forebrain regions (Dwivedi et al., 2005; Petty et al.,1997; Wu et al., 1999), suggesting that 
stress induces certain physiological abnormalities associated with anxiety disorders, 
possibly by impairing 5-HT2A signaling in the hypothalamus. One such physiological 
abnormality is sustained reduced body weight resulting from stress. Sustained body weight 
loss is a prominent feature observed in animals exposed to different stress paradigms. 
Weight loss has also been long regarded as a prominent symptom in certain patients with 
depression and anxiety disorders (Evers and Marin, 2002;Hirschfeld et al., 2005;Hopkinson, 
1981). This includes children with anxiety and stress disorder whose growth is stunted 
(Richards et al., 2006;Yorbik et al., 2004). Since the hypothalamic 5-HT2A receptor is 
particularly important in stress-related body weight change (Tao et al., 2002;Bah et al., 
2010;Rosmond et al., 1998) and mediation of energy homoeostasis (Halder et al., 2007),  
reduced hypothalamic 5-HT2A receptors may be a determining factor in the occurrence of 
severe weight loss (Kaye et al., 2005;Kaye et al., 2001;Bailer et al., 2004;Halder et al., 2007). 
Therefore, stress-induced decrease of 5-HT2A receptors in the hypothalamus may be the 
underlying mechanism for the sustained body weight loss in stressed animals. 
If this is the case, it would be expected that any condition preventing 5-HT2A receptor down 
regulaton , such as administration of a 5-HT2A antagonist during stress, would be able to 
avert the subsequent occurrence of sustained body loss in animals. One recent observation 
appears to support this contention; administration of the 5-HT2A antagonist MDL 11939 
during traumatic stress exposure reverses the sustained body weight loss in stressed 
subjects (Jiang et al., 2009), suggesting that the mechanisms underlying the long-lasting 
reduction in body weight involve a disturbance of 5-HT2A receptor signaling in certain brain 
regions, particularly the hypothalamus.  
6. Pharmacotherapy for anxiety disorders 
Since 5-HT2A receptor and 5-HT2C receptor signaling in the amygdala and hypothalamus 
may be critically involved in the pathophysiology of anxiety disorders, any agent which is 
able to specifically modulate 5-HT2A or 5-HT2C receptor signaling in the amygdala and 
hypothalamus has the potential to treat symptoms associated with various forms of anxiety 
disorders, including PTSD. Indeed, several clinical studies have shown that the 5-HT2 
receptor antagonist, nefazodone, is effective in improving symptoms of intrusion, avoidance 
and hyperarousal in a group of Vietnam veterans with chronic-refractory, combat-related 
PTSD (Neylan et al., 2003;Hertzberg et al., 2002;Garfield et al., 2001;Domon and Andersen, 
2000;Zisook et al., 2000;Davis et al., 2000;Mellman et al., 1999;Hidalgo et al., 1999;Davidson 
et al., 1998). In particular, substantial evidence supports 5-HT2A receptor antagonists for 
preventing the development of behavioral and physiological changes associated with 
anxiety disorders , suggesting that these antagonists are promising preventive agents in the 
fight against stress-associated disorders. Several novel, more selective 5-HT2A antagonists 
have recently been developed (Bartoszyk et al., 2003) and have been entered into clinical 
trials for treatments of schizophrenia and insomnia (de Paulis, 2001;Fish et al., 2005). These 
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drugs appear to be well tolerated by all study participants (David et al., 2004) and thus 
should also be entered into trials for anxiety disorders, especially PTSD. Among these 
antagonists, R-96544, a drug metabolized from an orally administrated predrug, R-102444, 
should be paid particular attention (Ogawa et al., 2005;Ogawa et al., 2004;Ogawa et al., 
2002;Tanaka et al., 2008). The pharmacological profile of R-96544 suggests this 5-HT2A 
receptor antagonist for easy oral administration in the battle field and on site of traumatic 
events, thus potentially making it an ideal drug for preventing the psychiatric consequences 
of trauma. 
7. Conclusion 
Evidence from different disciplines suggests that alterations of 5-HT2 receptor signaling may 
be a critical link in the pathogenesis of anxiety disorders.  5-HT2 receptor signaling in the 
amygdala and hypothalamus is particularly important in this respect since alterations of 
receptor signaling in these areas may be directly related to certain symptoms associated 
with anxiety disorders.  Pharmacotherapy tailored to modulating the effect of 5-HT2A and 
HT2C receptors in the these areas thus represents an important future direction in 
developing novel, more efficacious pharmacological agents for the symptoms associated 
with anxiety disorders, including PTSD. 
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